Cochrane · systematic review · CD004310

Megestrol acetate for treatment of anorexia‐cachexia syndrome

Ruiz Garcia, V, López‐Briz, E, Carbonell Sanchis, R, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 85.7%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Megestrol acetate for cachexia anorexia syndrome

Population: cachexia anorexia syndrome
7 questions
OutcomeEffectEvidenceStatus / GRADE
Appetite improvement compared with placebo Subjective sense of appetite, responses to
RR 2.19 [1.41, 3.4]5 studies · 699 participantsVery low
Downgraded: risk of bias, inconsistency
Weight improvement compared with placebo % of patients that improved their weight in kg
RR 1.51 [1.08, 2.11]10 studies · 1106 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Appetite improvement compared to other drugs Questionnaire of appetite rating
RR 1.03 [0.64, 1.67]1 study · 475 participantsLow
Downgraded: risk of bias
Weight improvement compared to other drugs % of patients that improved their weight in kg
RR 1.66 [1.09, 2.52]7 studies · 1131 participantsVery low
Downgraded: risk of bias, inconsistency
Deaths
RR 1.42 [1.04, 1.94]10 studies · 1307 participantsVery low
Downgraded: risk of bias, imprecision
Thromboembolic phenomena including thrombophlebitis
RR 1.84 [1.07, 3.18]11 studies · 1544 participantsVery low
Downgraded: risk of bias
Oedema
RR 1.36 [1.07, 1.72]12 studies · 2182 participantsVery low
Downgraded: risk of bias